From the Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stony Brook University Medical Center.
Correspondence to: Jignesh K. Patel, MD, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stony Brook University Medical Center, Health Sciences Center, T17-040, Stony Brook, NY 11794-8160; e-mail: firstname.lastname@example.org
Financial/nonfinancial disclosures: The author has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.
I read with great interest the article by Stefan et al1 in CHEST (January 2013) regarding early antibiotic use and clinical outcomes in patients hospitalized with an exacerbation of COPD being concomitantly treated with systemic steroids. The authors concluded that early antibiotic use in combination with steroids is associated with lower rates of in-hospital mortality in patients admitted with COPD exacerbations. Several concerning aspects about the statistical analysis in this study require further clarification.
First, because of the nature of observational studies and their inherent selection bias, the authors performed propensity score matching such that patients in the late or no antibiotic arm are matched one to one with the nearest patient in the early antibiotic arm. Given that propensity score matching accounts for covariates that predict receiving the treatment in question, I believe that the absence of variables such as severity of disease, history of allergies and adverse events related to antibiotic use, and history of resistant bacterial infections in the propensity score analysis cannot be ignored and are integral to acknowledge in the propensity scoring and multivariate models. Moreover, the subsequent analysis examining the impact of antibiotic administration and antibiotic choice on outcomes cannot be interpreted unless patients with antibiotic allergies or antibiotic-resistant infections were excluded or if these variables were accounted for in the subsequent multivariate analysis.
Second, it is important to note that there are data to suggest that all patients with COPD do not benefit equally from corticosteroids. Analyses from the multicenter SCCOPE (Systemic Corticosteroids in COPD Exacerbations) trial performed by the Veterans Affairs Cooperative Studies Program demonstrated that prior hospitalization for COPD in the preceding 2 years is associated with a more favorable response to systemic steroid use.2 Other clinical factors suggested to have an impact on steroid responsiveness were theophylline use, lower FEV1 at admission, and prior prednisone use. The latter two baseline characteristics were not taken into account by Stefan et al1 in the multivariate analysis examining outcomes. Ultimately, the question of optimal antibiotic choice in hospitalized patients with a COPD exacerbation remains to be answered, especially in an era of increasingly prevalent antibiotic resistance.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.